Switch from intravenous or intramuscular to subcutaneous hepatitis B immunoglobulin: effect on quality of life after liver transplantation

Switch from intravenous or intramuscular to subcutaneous hepatitis B immunoglobulin: effect on quality of life after liver transplantation

Abstract Background Hepatitis B immunoglobulin (HBIG) therapy is available in intravenous (IV) or intra-muscular (IM) formulations. Recently, a subcutaneous (SC) formulation was introduced. This study evaluated changes in quality of life when liver transplant (LT) recipients were switched from IV or...

Full description

Bibliographic Details
Main Authors: Riccardo Volpes, Patrizia Burra, Giacomo Germani, Matteo Angelo Manini, Lucio Caccamo, Paolo Strignano, Giorgia Rizza, Mariarosa Tamè, Antonio Daniele Pinna, Fulvio Calise, Carla Migliaccio, Paola Carrai, Paolo De Simone, Maria Filippa Valentini, Luigi Giovanni Lupo, Gabriella Cordone, Francesco Paolo Picciotto, Antonio Nicolucci
Format: Article
Language:English
Published: BMC 2020-04-01
Series:Health and Quality of Life Outcomes
Subjects:
Questionnaire
Satisfaction
Acceptability of treatment
Side effects
Patient autonomy
Online Access:http://link.springer.com/article/10.1186/s12955-020-01349-5

Internet

http://link.springer.com/article/10.1186/s12955-020-01349-5

Similar Items